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:   human epidermal growth factor Receptor
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:   triple‐negative breast cancer

TTC
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Introduction {#ijc32788-sec-0001}
============

Breast cancer is the most commonly diagnosed cancer and has the second‐highest mortality rate among women.[1](#ijc32788-bib-0001){ref-type="ref"} Patients diagnosed with high‐risk tumors such as triple‐negative breast cancer (TNBC) have an adverse prognosis compared to patients with other subtypes.[2](#ijc32788-bib-0002){ref-type="ref"} For these patients, locoregional treatment consists of breast‐conserving surgery (BCS) with radiation therapy or mastectomy with or without radiation therapy. Adjuvant chemotherapy is standard of care for patients with TNBC.[3](#ijc32788-bib-0003){ref-type="ref"}, [4](#ijc32788-bib-0004){ref-type="ref"} as the treatment reduces the risk on a distant recurrence and improves overall survival.[5](#ijc32788-bib-0005){ref-type="ref"}, [6](#ijc32788-bib-0006){ref-type="ref"}

Although an optimal interval from surgery to adjuvant chemotherapy (Time to Chemotherapy, TTC) is not precisely defined, guidelines recommend to initiate chemotherapy within 6--12 weeks after surgery.[7](#ijc32788-bib-0007){ref-type="ref"}, [8](#ijc32788-bib-0008){ref-type="ref"} Several studies showed an association between delayed initiation of chemotherapy and worse breast cancer outcomes, though with different cut‐off points between 6 and 12 weeks.[9](#ijc32788-bib-0009){ref-type="ref"}, [10](#ijc32788-bib-0010){ref-type="ref"}, [11](#ijc32788-bib-0011){ref-type="ref"}, [12](#ijc32788-bib-0012){ref-type="ref"} Although patients with TNBC are less likely to have delayed TTC compared to other subtypes,[13](#ijc32788-bib-0013){ref-type="ref"}, [14](#ijc32788-bib-0014){ref-type="ref"}, [15](#ijc32788-bib-0015){ref-type="ref"}, [16](#ijc32788-bib-0016){ref-type="ref"} between 35% and 74% of patients with TNBC receive adjuvant chemotherapy beyond 30 days after surgery.[9](#ijc32788-bib-0009){ref-type="ref"}, [10](#ijc32788-bib-0010){ref-type="ref"}, [16](#ijc32788-bib-0016){ref-type="ref"}, [17](#ijc32788-bib-0017){ref-type="ref"}, [18](#ijc32788-bib-0018){ref-type="ref"}

In the recent years, several studies have suggested that the impact of TTC on survival might be subtype‐dependent and that initiation of adjuvant chemotherapy within 30 days could be warranted particularly in patients with high‐risk breast cancer such as TNBC,[9](#ijc32788-bib-0009){ref-type="ref"}, [10](#ijc32788-bib-0010){ref-type="ref"}, [17](#ijc32788-bib-0017){ref-type="ref"}, [18](#ijc32788-bib-0018){ref-type="ref"} as this type has a more aggressive biology and rapid proliferation rate compared to other subtypes.[19](#ijc32788-bib-0019){ref-type="ref"} However, the current evidence that a TTC within 30 days is warranted in patients with TNBC is based on single‐center studies with weak methodology.[11](#ijc32788-bib-0011){ref-type="ref"} None of the previous studies stratified analyses for the type of surgery or adjusted for confounding by indication by matching patients on the likelihood to receive adjuvant chemotherapy within 30 days. This latter is crucial as patients with certain baseline characteristics, such as old age, use of breast reconstruction or hospital transfer, do not have the same chance of TTC within 30 days so that it is not clear whether it is the TTC or the underlying indication causing the reduced survival.[9](#ijc32788-bib-0009){ref-type="ref"}, [15](#ijc32788-bib-0015){ref-type="ref"}, [20](#ijc32788-bib-0020){ref-type="ref"} Furthermore, it is not always clear if previous studies excluded patients who received adjuvant radiation therapy before chemotherapy.

In the current study, we conducted a propensity score‐matched analysis in a prospective, population‐based cohort to assess the extent to which TTC beyond 30 days is associated with survival among patients diagnosed with TNBC. To further limit confounding by indication, we focused only on patients who underwent surgery followed by chemotherapy and stratified the analyses by type of surgery.

Methods {#ijc32788-sec-0002}
=======

Data were anonymously obtained from the Netherlands Cancer Registry (NCR). The NCR is a prospective nationwide register for all malignancies diagnosed in all hospitals in the Netherlands. Based on notification from the Pathology Archive (PALGA) it includes patient, tumor and treatment characteristics, which are registered by trained data managers. Vital status is regularly obtained in the NCR database through linkages with the municipality register. Our study has been approved by the privacy committee of the NCR.

All women diagnosed with Stage I--III TNBC between 2006 and 2014 who underwent breast‐conserving surgery (BCS) or a mastectomy were selected. The hormonal receptors were categorized as negative when \<10% of tumor cells were positively stained following the Dutch Breast Cancer guidelines. Human Epidermal growth factor Receptor (HER) 2 was defined negative in case of protein overexpression in an immunohistochemistry test or gene amplification in a fluorescence *in situ* hybridization test. TNBC was defined when estrogen‐negative, progesterone‐negative and HER2‐negative. For the current study, only TNBC patients who received adjuvant chemotherapy were selected. We excluded patients who were treated with radiotherapy before chemotherapy, as the current study focused on impact of delayed TTC and part of the delay could otherwise be due to delay in or recovery from radiotherapy. Furthermore, we excluded patients diagnosed with metachronous primary breast cancers, metastatic disease, treatment with neoadjuvant chemotherapy, unknown date of operation or start of chemotherapy as this makes calculation of TTC impossible. Patients with extreme TTCs beyond 6 months were also excluded as these were most likely data entry errors.

All patients received adjuvant chemotherapy according to the Dutch Breast Cancer Guidelines applicable at that point in time. Alterations to the guidelines were made in 2008 and 2012 which is shown in Supporting Information [Table S1](#ijc32788-supitem-0001){ref-type="supplementary-material"}. Every treatment schedule contained an Anthracycline. Since 2008 additionally a taxane was included for high‐risk patients.

Since baseline characteristics and breast cancer outcomes differ between the different types of surgery, patients were categorized into (*i*) patients who underwent BCS and (*ii*) patients who underwent mastectomy. The type of surgery was defined by the definitive surgery performed. TTC was defined as the number of days between definitive breast surgery and initiation of adjuvant chemotherapy. Type or moment of axillary surgery was not taken into account. Within each patient group, patients were categorized into two‐time interval groups; TTC ≤30 days and TTC \>30 days. The primary outcome of our study was 10‐year overall survival, which was defined as time from definitive surgery until last contact, being the date of death or last linkage of the NCR with the municipality register. The last linkage for the current study was on February 1, 2018.

To limit confounding by indication, a propensity score was created for having TTC beyond 30 days using a logistic regression model.[21](#ijc32788-bib-0021){ref-type="ref"} The following covariates were included in the propensity score; year of diagnosis, age, socioeconomic status (SES), histological tumor type, differentiation grade, stage, re‐excision and change of hospital after surgery. Patients were matched on having the same propensity for TTC \> 30 days using a matching ratio of 1:1.[22](#ijc32788-bib-0022){ref-type="ref"} The caliper width used in our analyses was 0.2 times the standard deviation of the logit of the propensity score. We checked for possible imbalance in baseline characteristics before and after matching using standardized differences. A standardized difference of a variable of ≥10% indicates an imbalance in baseline characteristics between the time interval groups.[23](#ijc32788-bib-0023){ref-type="ref"} Median follow‐up was determined using the reverse Kaplan--Meier method.[24](#ijc32788-bib-0024){ref-type="ref"} The 10‐year overall survival was estimated using the Kaplan--Meier method and compared between the matched time interval groups using the log‐rank test. The hazard ratios (HR) with 95% confidence intervals (CIs) for occurrence of death were determined using a Cox regression model in matched patients. We tested the proportionality assumption using log--log plots and Schoenfeld residuals which were all satisfied. To minimize the impact of radiotherapy after chemotherapy, subsequent analyses were conducted with patients who did and did not receive radiation therapy. All analyses were performed in STATA® version 14.2 (StataCorp LLC, College Station, TX).

Results {#ijc32788-sec-0004}
=======

The analyses included 3,016 patients, of whom 1,079 (35.8%) underwent BCS and 1,937 (64.2%) underwent mastectomy. The mean (standard deviation) age was 51.1 (10.7) and 50.9 (12.4) years at diagnosis for patients who underwent BCS and mastectomy, respectively.

Of the 1,079 patients who underwent BCS before matching, 485 (45.0%) patients received adjuvant chemotherapy ≤30 days and 594 (55.1%) patients \>30 days. Before matching, the absolute standardized difference was more than 10% in seven categories of baseline characteristics, suggesting an inadequate balance (Table [1](#ijc32788-tbl-0001){ref-type="table"}). In total, 452 (50.0%) patients with TTC \>30 days were successfully matched to 452 (50.0%) patients with TTC ≤30 days. In these patients, absolute standardized differences for the covariates, except the year of inclusion 2010, were \<10%, suggesting an overall adequate balance across the two TTC groups. For matched patients who underwent BCS within and beyond 30 days, median (interquartile range) TTC was 26 (22--28) days and 43 (35--72) days, respectively.

###### 

Comparison of baseline characteristics of patients who underwent breast‐conserving surgery according to time to chemotherapy ≤30 days and \>30 days before and after matching

                            Before matching (*n* = 1,079)   After matching (*n* = 904)                                         
  ------------------------- ------------------------------- ---------------------------- ----------- ------------ ------------ -----------
  Year of inclusion                                                                                                            
  2006                      32 (6.6)                        51 (8.6)                     0.075       31 (6.9)     27 (6.0)     0.036
  2007                      31 (6.4)                        42 (7.1)                     0.027       31 (6.9)     36 (8.0)     0.042
  2008                      55 (11.3)                       69 (11.6)                    0.009       54 (11.9)    59 (13.1)    0.033
  2009                      51 (10.5)                       71 (12.0)                    0.046       51 (11.3)    54 (11.9)    0.021
  2010                      57 (11.8)                       106 (17.9)                   **0.172**   57 (12.6)    37 (8.2)     **0.145**
  2011                      68 (14.0)                       74 (12.5)                    0.046       67 (14.8)    71 (15.7)    0.025
  2012                      70 (14.4)                       69 (11.6)                    0.084       63 (13.9)    67 (14.8)    0.025
  2013                      48 (9.9)                        64 (10.8)                    0.029       48 (10.6)    54 (11.9)    0.042
  2014                      73 (15.1)                       48 (8.1)                     **0.219**   50 (11.1)    47 (10.4)    0.021
  Age (years)                                                                                                                  
  \<40                      79 (16.3)                       93 (15.7)                    0.017       77 (17.0)    78 (17.3)    0.006
  40--49                    157 (32.4)                      147 (24.8)                   **0.169**   138 (30.5)   141 (31.2)   0.014
  50--59                    134 (27.6)                      198 (33.3)                   **0.124**   131 (29.0)   125 (27.7)   0.029
  60--69                    101 (20.8)                      140 (23.6)                   0.066       93 (20.6)    94 (20.8)    0.005
  ≥70                       14 (2.9)                        16 (2.7)                     0.012       13 (2.9)     14 (3.1)     0.013
  SES                                                                                                                          
  Low                       149 (30.7)                      183 (30.8)                   0.002       139 (30.8)   134 (29.6)   0.024
  Medium                    167 (34.4)                      199 (33.5)                   0.020       156 (34.5)   157 (34.7)   0.005
  High                      169 (34.9)                      212 (35.7)                   0.018       157 (34.7)   161 (35.6)   0.029
  Histological tumor type                                                                                                      
  Ductal                    436 (89.9)                      544 (91.6)                   0.058       410 (90.7)   407 (90.0)   0.023
  Lobular                   6 (1.2)                         6 (0.8)                      0.039       3 (0.7)      4 (0.9)      0.025
  Other                     43 (8.9)                        45 (7.6)                     0.047       39 (8.6)     41 (9.1)     0.016
  Differentiation grade                                                                                                        
  Well                      3 (0.6)                         6 (1.0)                      0.044       3 (0.7)      2 (0.4)      0.030
  Intermediate              58 (12.0)                       65 (10.9)                    0.032       48 (10.6)    53 (11.7)    0.035
  Poor                      419 (86.4)                      505 (85.0)                   0.039       396 (87.6)   395 (87.4)   0.007
  Unknown                   5 (1.0)                         18 (3.0)                     **0.142**   5 (1.1)      2 (0.4)      0.076
  Stage                                                                                                                        
  I                         136 (28.0)                      193 (32.5)                   0.096       134 (29.6)   124 (27.4)   0.049
  II                        286 (59.0)                      312 (52.5)                   **0.130**   259 (57.3)   266 (58.8)   0.031
  III                       63 (13.0)                       89 (15.0)                    0.058       59 (13.1)    62 (13.7)    0.019
  Re‐excision                                                                                                                  
  Yes                       33 (6.8)                        27 (4.6)                     0.098       22 (4.9)     24 (5.3)     0.020
  Change in hospital                                                                                                           
  Yes                       154 (31.8)                      217 (36.5)                   **0.101**   146 (32.3)   136 (30.1)   0.048

Note: Values are numbers (percentages) unless stated otherwise. Percentages may not add up to exactly 100% as a result of rounding.

A standardized difference of a variable of ≥10% is presented in bold. This indicates an imbalance in baseline characteristics between the time interval groups.

Abbreviations: SD, standard deviation; SES, socioeconomic status.

Of the 1937 patients who underwent mastectomy, 806 (41.6%) patients received adjuvant chemotherapy ≤30 days and 1,131 (58.4%) patients \>30 days after mastectomy. Before matching, patients showed a significant imbalance in four categories of baseline characteristics (Table [2](#ijc32788-tbl-0002){ref-type="table"}). In total, 784 (50.0%) patients with TTC \>30 days were successfully matched to 784 (50.0%) patients with TTC ≤30 days. After matching, imbalance in two groups remained (year of inclusion 2008 and age beyond 70). For matched patients who underwent mastectomy within and beyond 30 days, median (interquartile range) TTC was 26 (22--28) days and 38 (34--47) days, respectively. All subsequent analyses were performed in the matched patient populations.

###### 

Comparison of baseline characteristics of patients who underwent mastectomy according to time from surgery to chemotherapy ≤30 days and \>30 days before and after matching

                            Before matching (*n* = 1937)   After matching (*n* = 1,568)                                         
  ------------------------- ------------------------------ ------------------------------ ----------- ------------ ------------ -----------
  Year of inclusion                                                                                                             
  2006                      60 (7.4)                       83 (7.3)                       0.004       60 (7.7)     68 (8.7)     0.037
  2007                      71 (8.8)                       101 (8.9)                      0.004       69 (8.8)     77 (9.8)     0.035
  2008                      66 (8.2)                       129 (11.4)                     **0.108**   66 (8.4)     33 (4.2)     **0.174**
  2009                      89 (11.0)                      144 (12.7)                     0.052       89 (11.4)    91 (11.6)    0.008
  2010                      98 (12.2)                      160 (14.1)                     0.059       96 (12.2)    87 (11.1)    0.036
  2011                      118 (14.6)                     151 (13.4)                     0.037       116 (14.8)   120 (15.3)   0.014
  2012                      111 (13.8)                     148 (13.1)                     0.020       109 (13.9)   123 (15.7)   0.050
  2013                      112 (13.9)                     113 (10.0)                     **0.121**   104 (13.3)   104 (13.3)   0.000
  2014                      81 (10.0)                      102 (9.0)                      0.035       75 (9.6)     81 (10.3)    0.026
  Age (years)                                                                                                                   
  \<40                      216 (26.8)                     214 (18.9)                     **0.188**   199 (25.4)   206 (26.3)   0.020
  40--49                    195 (24.2)                     277 (24.5)                     0.007       193 (24.6)   206 (26.3)   0.038
  50--59                    196 (24.3)                     280 (24.8)                     0.010       193 (24.6)   215 (27.4)   0.064
  60--69                    172 (21.3)                     283 (25.0)                     0.087       172 (21.9)   153 (19.5)   0.060
  ≥70                       27 (3.3)                       77 (6.8)                       **0.158**   27 (3.4)     4 (0.5)      **0.212**
  SES                                                                                                                           
  Low                       263 (32.6)                     256 (31.5)                     0.025       255 (32.5)   262 (33.4)   0.019
  Medium                    276 (34.2)                     378 (33.4)                     0.017       271 (34.6)   272 (34.7)   0.003
  High                      267 (33.1)                     397 (35.1)                     0.042       258 (32.9)   250 (31.9)   0.022
  Histological tumor type                                                                                                       
  Ductal                    722 (89.6)                     1,034 (91.4)                   0.063       705 (89.9)   702 (89.5)   0.013
  Lobular                   20 (2.5)                       20 (1.8)                       0.049       20 (2.6)     18 (2.3)     0.017
  Other                     64 (7.9)                       77 (6.8)                       0.043       59 (7.5)     64 (8.2)     0.024
  Differentiation grade                                                                                                         
  Well                      6 (0.7)                        10 (0.9)                       0.016       6 (0.8)      4 (0.5)      0.032
  Intermediate              113 (14.0)                     143 (12.6)                     0.040       109 (13.9)   118 (15.1)   0.033
  Poor                      672 (83.4)                     960 (84.9)                     0.041       656 (83.7)   649 (82.8)   0.024
  Unknown                   15 (1.9)                       18 (1.6)                       0.021       13 (1.7)     13 (1.7)     0.000
  Stage                                                                                                                         
  I                         185 (23.0)                     307 (27.1)                     0.097       182 (23.2)   173 (22.1)   0.027
  II                        467 (57.9)                     616 (54.5)                     0.070       453 (57.8)   466 (59.4)   0.034
  III                       154 (19.1)                     208 (18.4)                     0.018       149 (19.0)   145 (18.5)   0.013
  Re‐excision                                                                                                                   
  Yes                       69 (8.6)                       73 (6.5)                       0.080       63 (8.0)     67 (8.5)     0.019
  Change of hospital                                                                                                            
  Yes                       269 (33.4)                     413 (36.5)                     0.066       267 (34.1)   261 (33.3)   0.016
  IBR                                                                                                                           
  Yes                       93 (11.5)                      146 (12.9)                     0.042       93 (11.9)    90 (11.5)    0.012

Note: Values are numbers (percentages) unless stated otherwise. Percentages may not add up to exactly 100% as a result of rounding.

A standardized difference of a variable of ≥10% is presented in bold. This indicates an imbalance in baseline characteristics between the time interval groups.

Abbreviations: IBR, immediate breast reconstruction; SES, socioeconomic status.

Median follow‐up was 82.9 (95% CI: 80.5--86.5) and 81.4 (95% CI: 79.5--83.9) months for patients who underwent BCS and mastectomy, respectively. During the study period, 157 (17.2%) of the BCS matched patients died. In these matched patients undergoing BCS, 10‐year overall survival was significantly better in patients with TTC ≤30 days compared to patients with TTC \> 30 days (84.4% \[95% CI 79.7--88.1\] *vs*. 76.9% \[95% CI 72.2--81.0\], *p* = 0.001) as shown in Figure [1](#ijc32788-fig-0001){ref-type="fig"}. Patients with TTC \>30 days were more likely than those with TTC ≤30 days to die within 10 years after surgery (HR 1.69 (95% CI 1.22--2.34), *p* = 0.002). During the study period, 349 (22.3%) of the mastectomy matched patients died. In matched patients undergoing mastectomy, 10‐year overall survival was similar between patients with TTC ≤30 days and patients with TTC \> 30 days (74.5% \[95% CI 70.6--77.9\] *vs*. 74.7% \[95% CI 70.9--78.1\], *p* = 0.716) as shown in Figure [2](#ijc32788-fig-0002){ref-type="fig"}. Patients with TTC \>30 days had the same likelihood as patients with TTC ≤30 days to die within 10 years after surgery (HR 1.04 \[95% CI 0.84--1.28\], *p* = 0.716).

![Ten‐years overall survival for matched patients who underwent breast‐conserving surgery with time from surgery to chemotherapy ≤30 days and \>30 days. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-147-152-g001){#ijc32788-fig-0001}

![Ten‐years overall survival for matched patients who underwent mastectomy with time from surgery to chemotherapy ≤30 days and \>30 days. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-147-152-g002){#ijc32788-fig-0002}

A small number of patients who underwent BCS did not receive radiotherapy after chemotherapy (*n* = 53). To limit the potential impact of the use of radiotherapy after chemotherapy on overall survival, subsequent analyses were performed in BCS matched patients who received radiotherapy (*n* = 880). In this subgroup, the increased likelihood to die within 10 years associated with TTC \> 30 days remained (HR 1.58 \[95% CI 1.13--2.22\], *p* = 0.008). In patients who underwent mastectomy, 1,461 (75.4%) patients did not receive radiotherapy after chemotherapy. In the subgroup analyses of patients who did not receive radiotherapy (*n* = 1,128), patients with TTC \> 30 days had a similar 10‐year overall survival compared to patients with TTC ≤30 days (HR 1.10 \[95% CI 0.83--1.47\], *p* = 0.500). The same was found in matched patients who did receive radiotherapy after chemotherapy (*n* = 342, HR 0.98 \[95% CI 0.70--1.39\], *p* = 0.930).

Discussion {#ijc32788-sec-0005}
==========

In this population‐based cohort study, we demonstrated that in propensity‐score matched patients diagnosed with TNBC who underwent BCS with TTC beyond 30 days was associated with a significantly increased risk of death compared to those with a TTC within 30 days, while a TTC beyond 30 days had no impact on survival for patients undergoing a mastectomy. Furthermore, we demonstrated that this association was independent of the use of adjuvant radiotherapy after chemotherapy. These results suggest timelier initiation of chemotherapy in TNBC patients is warranted after BCS, which is relevant because previous studies showed delay beyond 30 days to occur in a substantial proportion of these patients.

Even though current literature does not clearly state the optimal timing for adjuvant chemotherapy for all patients, consensus exists on a more aggressive treatment for TNBC as it has a more aggressive biology and rapid proliferation rate compared to other subtypes.[4](#ijc32788-bib-0004){ref-type="ref"}, [8](#ijc32788-bib-0008){ref-type="ref"}, [19](#ijc32788-bib-0019){ref-type="ref"} Therefore, it makes sense that timely adjuvant chemotherapy is particularly relevant for these patients. Adjuvant chemotherapy improves breast cancer outcomes especially by the cytotoxic effects on micrometastases. Possible explanations for the decrease in overall survival in patients with delayed TTC include increased angiogenesis in the tumor and growth of distant micrometastases, given that TNBC is characterized by rapid growth which is now given more time due to delay in TTC.[19](#ijc32788-bib-0019){ref-type="ref"} The current study adds to the current evidence that the association is only present in patients who underwent BCS and not in those who underwent mastectomy, as previous studies did not stratify analyses for type of surgery.[11](#ijc32788-bib-0011){ref-type="ref"} It is possible that the impact on survival after BCS is due to patient selection. Patients preference for BCS and less significant surgery can be related to comorbidity or frailty as well as be the reason for delayed TTC, which independently may impact patients' survival.[25](#ijc32788-bib-0025){ref-type="ref"} This might also explain a smaller impact on survival in patients who underwent mastectomy as these patients are known to have more comorbidities compared to those who underwent BCS.[25](#ijc32788-bib-0025){ref-type="ref"} Unfortunately, comorbidities and frailty measures are not registered in the NCR‐database and could therefore not be included in the current study.

Another explanation for the different association of TTC and overall survival between the two surgical procedures may be found in the different range of TTC among patients who underwent BCS with TTC beyond 30 days (median 43 days, interquartile range 35--72 days) compared to those who underwent mastectomy with TTC beyond 30 days (median 38 days, interquartile range 34--47 days). However, subsequent multivariable analyses categorizing patients into three‐time interval groups showed that both patients who underwent mastectomy with TTC between 31 and 60 days and beyond 60 days had a similar survival compared to those with TTC within 30 days (data not shown), despite the small number of patients with TTC beyond 60 days (*n* = 121).

Most previous studies reported an association between delayed TTC in TNBC patients and adverse outcomes.[11](#ijc32788-bib-0011){ref-type="ref"} Two studies reported an average 26% significantly increased risk of death in patients with TNBC who have TTC between 31 and 60 days compared to those with TCC within 30 days.[9](#ijc32788-bib-0009){ref-type="ref"}, [10](#ijc32788-bib-0010){ref-type="ref"} More recently, Yu *et al*. reported in a subgroup analyses (*n* = 270) that TNBC patients who had TTC beyond 8 weeks have a worse OS (HR 2.55, 95% CI 1.25--5.18).[18](#ijc32788-bib-0018){ref-type="ref"} Unfortunately, these three studies did not stratify analyses for the type of definitive surgery nor performed subgroup analyses for use of radiotherapy. The observed association in these three studies might thus be biased due to difference in prognosis between provided treatment or due to insufficiently adjusting for unbalanced baseline characteristics. In the current study, an imbalance in baseline characteristics was seen before matching between patients who received adjuvant chemotherapy within and beyond 30 days. These characteristics could also be underlying indications for timelier initiation of chemotherapy. Poor prognostic characteristics such as older age, higher differentiation grade, triple‐negative receptor status and lymph node involvement are associated with reduced TTC in many previous studies, despite using different time thresholds. Since these poor prognostic characteristics influence both the indication for timelier initiation as well as the outcome, estimating a reliable effect of TTC on survival as performed in our study demanded adjustment for this confounding by indication. Still, we cannot rule out residual confounding by unmeasured factors (i.e., comorbidity of dose‐intensity of chemotherapy).

In contrast with the previously mentioned studies, a recent propensity score‐matched single‐center study in 724 TNBC patients observed no difference in disease‐free survival and overall survival between patients who had TTC within 30, 32--42, 43--56 or beyond 56 days.[26](#ijc32788-bib-0026){ref-type="ref"} The difference in results with the current study might be due to the smaller sample size or absence of stratified analyses for type of surgery. Moreover, the single‐center setting decreases the generalizability of the former results due to local clinical practice.

Most previous studies did not specify if adjuvant chemotherapy was initiated before or after radiotherapy.[11](#ijc32788-bib-0011){ref-type="ref"} The exclusion of patients who received radiotherapy before chemotherapy in the current study is essential to obtain reliable results, as there is a significant difference in baseline characteristics and breast cancer outcomes between those who receive chemotherapy before or after radiotherapy.[27](#ijc32788-bib-0027){ref-type="ref"}

In high‐income countries, today\'s tendency is to give chemotherapy in the neoadjuvant setting, thus before surgery, specifically for patients with locally advanced breast cancer aged \<70 years.[28](#ijc32788-bib-0028){ref-type="ref"} For our study, the number of neoadjuvant treated patients was too low and follow‐up since introduction in the Netherlands was too short to make reliable conclusions. In future research, it would be interesting to evaluate the impact of time to treatment on survival in patients with TNBC.

Our study has several limitations. First, we could only adjust for confounding by indication of measured and known variables, but several unknown as well as unmeasured confounders could influence the outcomes. For instance, the absence of information regarding the reason for the delayed TTC limits the interpretation of the association. There are several valid reasons that could delay TTC rather than being poor quality of delivered care which are associated with worse overall survival, such as complications due to the surgery, poor physical health, ECOG performance status or comorbidities that do not allow timelier initiation of chemotherapy. This information is not registered in the NCR database and could therefore not be included in our analyses, but might influence results if distributed differently between patient groups or time intervals. Comorbidity was only registered for a small percentage of the current population that this factor, unfortunately, could not be analyzed. Second, the results of the current study need to be evaluated in a large cohort including additional information regarding the chemotherapy type, dose, number of cycles and rate of completion as these are known to influence survival. This information was not included in the current overall analyses, as the type of chemotherapy is considered incomplete in the NCR before 2011. Nonetheless, analysis of a subgroup of patients treated between 2011 and 2014 while adjusting for type of chemotherapy (anthracycline, taxanes or a combination of both; data not shown), both for patients who underwent BCS and mastectomy, revealed similar results even despite the short follow‐up. A strength of the present study is both its sample size, stratified analyses by type of surgery and strong methodology to reduce confounding by indication given the impossibility to randomize patients by TTC.

Conclusions {#ijc32788-sec-0006}
===========

The current results suggest that the initiation of chemotherapy beyond 30 days is associated with decreased overall survival in TNBC patients who underwent BCS. However, no association was observed for those who underwent mastectomy. These results suggest timelier initiation of chemotherapy in TNBC patients is warranted after BCS.
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###### 

**Table S1** Dose and intensity schedule of chemotherapy for patients diagnosed with triple‐negative breast cancer according to the Dutch Breast Cancer Treatment guidelines between 2004 and 2014

###### 

Click here for additional data file.
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